Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.

Kudo M, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, Takita M, Hagiwara S, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Wada Y, Ikeda M, Ishii H, Izumi N, Nishida N.

Cancers (Basel). 2019 Jul 31;11(8). pii: E1084. doi: 10.3390/cancers11081084.

2.

Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study.

Ueshima K, Nishida N, Hagiwara S, Aoki T, Minami T, Chishina H, Takita M, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Hiraoka A, Johnson P, Kudo M.

Cancers (Basel). 2019 Jul 7;11(7). pii: E952. doi: 10.3390/cancers11070952.

3.

Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.

Arizumi T, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Kamata K, Minaga K, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M.

Dig Dis. 2017;35(6):589-597. doi: 10.1159/000480208. Epub 2017 Oct 17.

PMID:
29040992
4.

Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2.

Arizumi T, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Kamata K, Minaga K, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M.

Dig Dis. 2017;35(6):583-588. doi: 10.1159/000480186. Epub 2017 Oct 17.

PMID:
29040991
5.

Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.

Ida H, Hagiwara S, Kono M, Minami T, Chishina H, Arizumi T, Takita M, Yada N, Minami Y, Ueshima K, Nishida N, Kudo M.

Dig Dis. 2017;35(6):565-573. doi: 10.1159/000480183. Epub 2017 Oct 17.

PMID:
29040989
6.

Unique Characteristics Associated with Sustained Liver Damage in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals.

Kono M, Nishida N, Hagiwara S, Minami T, Chishina H, Arizumi T, Minaga K, Kamata K, Komeda Y, Sakurai T, Takenaka M, Takita M, Yada N, Ida H, Minami Y, Ueshima K, Watanabe T, Kudo M.

Dig Dis. 2017;35(6):556-564. doi: 10.1159/000480148. Epub 2017 Oct 17.

PMID:
29040988
7.

Hepatocarcinogenesis Is Associated with Serum Albumin Levels after Sustained Virological Responses with Interferon-Based Therapy in Patients with Hepatitis C.

Umehara Y, Hagiwara S, Nishida N, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Chishina H, Ueshima K, Komeda Y, Arizumi T, Watanabe T, Kudo M.

Dig Dis. 2017;35(6):548-555. doi: 10.1159/000480147. Epub 2017 Oct 17.

PMID:
29040987
8.

The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization.

Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M.

Liver Cancer. 2017 Jun;6(3):227-235. doi: 10.1159/000475777. Epub 2017 May 9.

9.

Malignant Transformation of Hepatocellular Adenoma.

Kwok WY, Hagiwara S, Nishida N, Watanabe T, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Iwanishi M, Chishina H, Kono M, Ueshima K, Komeda Y, Arizumi T, Enoki E, Nakai T, Kumabe T, Nakashima O, Kondo F, Kudo M.

Oncology. 2017;92 Suppl 1:16-28. doi: 10.1159/000451012. Epub 2016 Dec 17.

10.

Contrast-Enhanced Tissue Harmonic Imaging versus Phase Inversion Harmonic Sonographic Imaging for the Delineation of Hepatocellular Carcinomas.

Kono M, Minami Y, Iwanishi M, Minami T, Chishina H, Arizumi T, Komeda Y, Sakurai T, Takita M, Yada N, Ida H, Hagiwara S, Ueshima K, Nishida N, Kudo M.

Oncology. 2017;92 Suppl 1:29-34. doi: 10.1159/000451014. Epub 2016 Dec 15.

11.

Outcome of Combination Therapy with Sofosbuvir and Ledipasvir for Chronic Type C Liver Disease.

Hagiwara S, Nishida N, Watanabe T, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Iwanishi M, Chishina H, Ueshima K, Komeda Y, Arizumi T, Kudo M.

Oncology. 2017;92 Suppl 1:3-9. doi: 10.1159/000451010. Epub 2016 Dec 15.

12.

Cases with Refractory Ascites and a Delayed Response to Tolvaptan.

Hagiwara S, Nishida N, Chishina H, Ida H, Sakurai T, Komeda Y, Kitano M, Kudo M.

Intern Med. 2016;55(22):3273-3277. Epub 2016 Nov 15.

13.

US-US Fusion Imaging in Radiofrequency Ablation for Liver Metastases.

Minami Y, Minami T, Chishina H, Kono M, Arizumi T, Takita M, Yada N, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M.

Dig Dis. 2016;34(6):687-691. Epub 2016 Oct 17.

PMID:
27750238
14.

Validation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular Carcinoma.

Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Ida H, Sakurai T, Kitano M, Nishida N, Kudo M.

Dig Dis. 2016;34(6):671-678. Epub 2016 Oct 17.

PMID:
27750236
15.

Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.

Chishina H, Hagiwara S, Nishida N, Ueshima K, Sakurai T, Ida H, Minami Y, Takita M, Kono M, Minami T, Iwanishi M, Umehara Y, Watanabe T, Komeda Y, Arizumi T, Kudo M.

Dig Dis. 2016;34(6):659-664. Epub 2016 Oct 17.

PMID:
27750234
16.

Safety, Tolerability, and Efficacy of Sofosbuvir Plus Ribavirin in Elderly Patients Infected with Hepatitis C Virus Genotype 2.

Nishida N, Kono M, Minami T, Chishina H, Arizumi T, Takita M, Yada N, Ida H, Hagiwara S, Minami Y, Ueshima K, Sakurai T, Kudo M.

Dig Dis. 2016;34(6):632-639. Epub 2016 Oct 17.

PMID:
27750230
17.

Outcome of Asunaprevir/Daclatasvir Combination Therapy for Chronic Liver Disease Type C.

Hagiwara S, Nishida N, Watanabe T, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Iwanishi M, Chishina H, Ueshima K, Komeda Y, Arizumi T, Kudo M.

Dig Dis. 2016;34(6):620-626. Epub 2016 Oct 17.

PMID:
27750228
18.

Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma.

Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M.

Liver Cancer. 2015 Dec;4(4):253-62. doi: 10.1159/000367743. Epub 2015 Oct 21.

19.

Validation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular Carcinoma.

Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Ida H, Minami Y, Sakurai T, Kitano M, Nishida N, Kudo M.

Oncology. 2015;89 Suppl 2:47-52. doi: 10.1159/000440631. Epub 2015 Nov 19.

PMID:
26584036
20.

Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience.

Minami Y, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Tsurusaki M, Yagyu Y, Ueshima K, Nishida N, Murakami T, Kudo M.

Oncology. 2015;89 Suppl 2:27-32. doi: 10.1159/000440628. Epub 2015 Nov 19.

PMID:
26584033

Supplemental Content

Loading ...
Support Center